{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:18:31Z","timestamp":1789525111236,"version":"build-2803163510"},"reference-count":124,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI189313"],"award-info":[{"award-number":["AI189313"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI111914"],"award-info":[{"award-number":["AI111914"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI184623"],"award-info":[{"award-number":["AI184623"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI161943"],"award-info":[{"award-number":["AI161943"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI138587"],"award-info":[{"award-number":["AI138587"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI134240"],"award-info":[{"award-number":["AI134240"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tim.2025.11.003","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:40:08Z","timestamp":1764308408000},"page":"293-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Type I interferons in tuberculosis pathogenesis and prevention"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8122-7132","authenticated-orcid":false,"given":"Caden W.","family":"Munson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-1257","authenticated-orcid":false,"given":"Deepak","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2025.11.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2023.102371","article-title":"Tuberculosis in mummies \u2013 new findings, perspectives and limitations","volume":"143","author":"Zink","year":"2023","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tim.2025.11.003_bb0010","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/s41467-021-22833-6","article-title":"Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens","volume":"12","author":"Walter","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiz430","article-title":"Effectiveness of BCG vaccination against Mycobacterium tuberculosis infection in adults: a cross-sectional analysis of a UK-based cohort","volume":"221","author":"Katelaris","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0020","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3389\/fimmu.2017.01633","article-title":"Type I Interferons in the pathogenesis of tuberculosis: molecular drivers and immunological consequences","volume":"8","author":"Donovan","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0025","first-page":"258","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.tim.2025.11.003_bb0030","first-page":"282","article-title":"Membrane receptors for interferon","volume":"35","author":"Besan\u00e7on","year":"1977","journal-title":"Tex. Rep. Biol. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41467-022-28315-7","article-title":"Myeloid cell interferon responses correlate with clearance of SARS-CoV-2","volume":"13","author":"Singh","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0040","first-page":"1","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tim.2025.11.003_bb0045","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.chom.2016.05.016","article-title":"The roles of Type I Interferon in bacterial infection","volume":"19","author":"Boxx","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005408","article-title":"IFNs modify the proteome of legionella-containing vacuoles and restrict infection Via IRG1-derived itaconic acid","volume":"12","author":"Naujoks","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2025.11.003_bb0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.20091746","article-title":"Induction of IFN-alphabeta enables Listeria monocytogenes to suppress macrophage activation by IFN-gamma","volume":"207","author":"Rayamajhi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0060","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.vaccine.2011.12.111","article-title":"Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice","volume":"30","author":"Flach","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2025.11.003_bb0065","first-page":"1931","article-title":"Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A","volume":"119","author":"Martin","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.11.003_bb0070","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20180325","article-title":"Type I interferons in tuberculosis: foe and occasionally friend","volume":"215","author":"Moreira-Teixeira","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0075","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/jb.129.2.616-622.1977","article-title":"Rate of ribonucleic acid chain growth in Mycobacterium tuberculosis H37Rv","volume":"129","author":"Harshey","year":"1977","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.tim.2025.11.003_bb0080","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","article-title":"Drug resistant TB \u2013 latest developments in epidemiology, diagnostics and management","volume":"124","author":"Tiberi","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0085","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2881","article-title":"Overview of the biology of type I interferons","volume":"12","author":"Kalliolias","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tim.2025.11.003_bb0090","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of Type I and Type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.tim.2025.11.003_bb0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08830189809084487","article-title":"Type I interferons","volume":"17","author":"De Maeyer","year":"1998","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.605673","article-title":"Shared and unique features of human interferon-beta and interferon-alpha subtypes","volume":"11","author":"Wittling","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0105","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","article-title":"The molecular basis for differential type I interferon signaling","volume":"292","author":"Schreiber","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tim.2025.11.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70109","article-title":"NRF2 Antioxidant response and interferon-stimulated genes are differentially expressed in SARS-CoV-2-positive young subjects","volume":"13","author":"Toscanelli","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.tim.2025.11.003_bb0120","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1073\/pnas.91.17.7995","article-title":"Mechanism of interferon action: structure of the mouse PKR gene encoding the interferon-inducible RNA-dependent protein kinase","volume":"91","author":"Tanaka","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2025.11.003_bb0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41590-019-0323-3","article-title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape","volume":"20","author":"Hubel","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0135","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701120","article-title":"ISG15-induced IL-10 is a novel anti-inflammatory myeloid axis disrupted during active tuberculosis","volume":"200","author":"Dos Santos","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0140","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","article-title":"Regulation of effector and memory T-cell functions by type I interferon","volume":"132","author":"Huber","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.tim.2025.11.003_bb0150","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0155","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2021.03.006","article-title":"Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells","volume":"54","author":"Krueger","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.tim.2025.11.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017364","article-title":"Interferon-\u03b1-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12","volume":"6","author":"Santini","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2025.11.003_bb0165","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/toxins6061696","article-title":"Type I interferons as regulators of human antigen presenting cell functions","volume":"6","author":"Gessani","year":"2014","journal-title":"Toxins"},{"key":"10.1016\/j.tim.2025.11.003_bb0170","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.4049\/jimmunol.181.12.8204","article-title":"Cutting edge: a T-bet-independent role for IFN-alpha\/beta in regulating IL-2 secretion in human CD4+ central memory T cells","volume":"181","author":"Davis","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0175","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.1233665","article-title":"Type I interferon suppresses Type II interferon\u2013triggered human anti-mycobacterial responses","volume":"339","author":"Teles","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.tim.2025.11.003_bb0180","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41564-019-0578-3","article-title":"Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra","volume":"4","author":"Ji","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.tim.2025.11.003_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0190","first-page":"1","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tim.2025.11.003_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4049\/jimmunol.1901511","article-title":"TRIM14 is a key regulator of the Type I IFN response during Mycobacterium tuberculosis infection","volume":"205","author":"Hoffpauir","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0200","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.4049\/jimmunol.1401088","article-title":"Type I IFN Induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-\u03b3 for production of IL-12 and bacterial killing in Mycobacterium tuberculosis\u2013infected macrophages","volume":"193","author":"McNab","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.chom.2018.08.001","article-title":"Alveolar macrophages provide an early Mycobacterium tuberculosis niche and initiate dissemination","volume":"24","author":"Cohen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0210","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/cmi.12480","article-title":"The innate immune response in human tuberculosis","volume":"17","author":"Lerner","year":"2015","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.tim.2025.11.003_bb0215","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41579-022-00763-4","article-title":"Immune evasion and provocation by Mycobacterium tuberculosis","volume":"20","author":"Chandra","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tim.2025.11.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01456-22","article-title":"TREM2 promotes immune evasion by Mycobacterium tuberculosis in human macrophages","volume":"13","author":"Dabla","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.tim.2025.11.003_bb0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.chom.2020.11.013","article-title":"The immune landscape in tuberculosis reveals populations linked to disease and latency","volume":"29","author":"Esaulova","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0230","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.chom.2015.05.005","article-title":"Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis","volume":"17","author":"Collins","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0235","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chom.2015.05.003","article-title":"Mycobacterium tuberculosis differentially activates cGAS- and inflammasome-dependent intracellular immune responses through ESX-1","volume":"17","author":"Wassermann","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0240","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1084\/jem.20180508","article-title":"Mycobacterium tuberculosis\u2013induced IFN-\u03b2 production requires cytosolic DNA and RNA sensing pathways","volume":"215","author":"Cheng","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067277","article-title":"Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response","volume":"8","author":"Carmona","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2025.11.003_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2021.106946","article-title":"Mitochondrial DNA and TLR9 activation contribute to SARS-CoV-2-induced endothelial cell damage","volume":"142","author":"Costa","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.tim.2025.11.003_bb0255","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s41467-018-04579-w","article-title":"A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection","volume":"9","author":"Singhania","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110983","article-title":"Mycobacterium tuberculosis infection drives a type I IFN signature in lung lymphocytes","volume":"39","author":"Akter","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.tim.2025.11.003_bb0265","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4049\/jimmunol.2101029","article-title":"Modern clinical Mycobacterium tuberculosis strains leverage Type I IFN pathway for a proinflammatory response in the host","volume":"209","author":"Shankaran","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0270","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1089\/jir.2005.25.694","article-title":"Hypervirulent M. tuberculosis W\/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway","volume":"25","author":"Manca","year":"2005","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.tim.2025.11.003_bb0275","first-page":"423","article-title":"The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection","volume":"84","author":"Cooper","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.tim.2025.11.003_bb0280","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.tim.2025.11.003_bb0285","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1084\/jem.178.6.2243","article-title":"Disseminated tuberculosis in interferon gamma gene-disrupted mice","volume":"178","author":"Cooper","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0290","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/7701","article-title":"A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection","volume":"21","author":"Jouanguy","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tim.2025.11.003_bb0295","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1\u2013neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0300","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.4049\/jimmunol.1200255","article-title":"Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis","volume":"188","author":"Desvignes","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0305","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09247","article-title":"An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis","volume":"466","author":"Berry","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.tim.2025.11.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006687","article-title":"Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease","volume":"13","author":"Scriba","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2025.11.003_bb0315","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.micinf.2016.12.006","article-title":"The impact of ISGylation during Mycobacterium tuberculosis infection in mice","volume":"19","author":"Kimmey","year":"2017","journal-title":"Microbes Infect."},{"key":"10.1016\/j.tim.2025.11.003_bb0320","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.immuni.2011.12.002","article-title":"Innate and adaptive interferons suppress IL-1\u03b1 and IL-1\u03b2 production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection","volume":"35","author":"Mayer-Barber","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.tim.2025.11.003_bb0325","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1172\/JCI40817","article-title":"Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte\/macrophage population","volume":"120","author":"Antonelli","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.11.003_bb0330","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4049\/jimmunol.178.5.3143","article-title":"The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis1","volume":"178","author":"Stanley","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0335","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1038\/s41467-020-19412-6","article-title":"Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis","volume":"11","author":"Moreira-Teixeira","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0340","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tube.2013.09.004","article-title":"Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis","volume":"94","author":"Marzo","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tim.2025.11.003_bb0345","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0684.2012.00536.x","article-title":"The non-human primate model of tuberculosis","volume":"41","author":"Kaushal","year":"2012","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.tim.2025.11.003_bb0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrmicro1538","article-title":"Who puts the tubercle in tuberculosis?","volume":"5","author":"Russell","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tim.2025.11.003_bb0355","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153090","article-title":"Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis\/SIV coinfection model","volume":"132","author":"Sharan","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.11.003_bb0360","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.4049\/jimmunol.1801135","article-title":"Friend or foe: the protective and pathological roles of inducible bronchus-associated lymphoid tissue in pulmonary diseases","volume":"202","author":"Marin","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0365","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41590-023-01476-3","article-title":"Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control","volume":"24","author":"Swanson","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0370","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221392","article-title":"Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis","volume":"220","author":"Sawyer","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0375","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/v17020139","article-title":"The role of sustained Type I interferon secretion in chronic HIV pathogenicity: implications for viral persistence, immune activation, and immunometabolism","volume":"17","author":"Teer","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.tim.2025.11.003_bb0380","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1016\/j.cell.2023.11.002","article-title":"Early cellular mechanisms of type I interferon-driven susceptibility to tuberculosis","volume":"186","author":"Kotov","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tim.2025.11.003_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109195","article-title":"Type I interferon decreases macrophage energy metabolism during mycobacterial infection","volume":"35","author":"Olson","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.tim.2025.11.003_bb0390","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1038\/s44319-024-00171-0","article-title":"Type I interferon exacerbates Mycobacterium tuberculosis induced human macrophage death","volume":"25","author":"Lee","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.tim.2025.11.003_bb0395","article-title":"Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death","volume":"218","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0400","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/eji.201344219","article-title":"Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics","volume":"44","author":"Dorhoi","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0405","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1462-5822.2012.01783.x","article-title":"Escape of Mycobacterium tuberculosis from oxidative killing by neutrophils","volume":"14","author":"Corleis","year":"2012","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.tim.2025.11.003_bb0410","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.09-0903","article-title":"Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB","volume":"137","author":"Eum","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.tim.2025.11.003_bb0415","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.chom.2012.07.009","article-title":"Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages","volume":"12","author":"Yang","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0420","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.mucimm.2024.05.007","article-title":"Metabolically active neutrophils represent a permissive niche for Mycobacterium tuberculosis","volume":"17","author":"Andrews","year":"2024","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115072","article-title":"Pathogenic role for CD101-negative neutrophils in the type I interferon-mediated immunopathogenesis of tuberculosis","volume":"44","author":"Saqib","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.tim.2025.11.003_bb0430","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350666","article-title":"Neutrophil-plasmacytoid dendritic cell interaction leads to production of type I IFN in response to Mycobacterium tuberculosis","volume":"54","author":"Lee","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0435","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12931-017-0663-1","article-title":"Neutrophil extracellular traps in patients with pulmonary tuberculosis","volume":"18","author":"van der Meer","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.tim.2025.11.003_bb0440","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/infdis\/jix626","article-title":"Mycobacterium tuberculosis and HIV coinfection brings fire and fury to macrophages","volume":"217","author":"Khan","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0445","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1164\/ajrccm.158.4.9803065","article-title":"Effects of aerosolized interferon- \u03b1 in patients with pulmonary tuberculosis","volume":"158","author":"Giosu\u00e8","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0450","first-page":"29","article-title":"The efficacy of interferon-\u03b1 in the treatment of multidrug resistant tuberculosis","volume":"1","author":"Mansoori","year":"2002","journal-title":"TANAFFOS (Respiration)"},{"key":"10.1016\/j.tim.2025.11.003_bb0455","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1179\/1973947812Y.0000000005","article-title":"The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in non-responding tuberculosis and diabetes mellitus: a case report and review of the literature","volume":"24","author":"Zarogoulidis","year":"2012","journal-title":"J. Chemother."},{"key":"10.1016\/j.tim.2025.11.003_bb0460","first-page":"99","article-title":"Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis","volume":"11","author":"Giosu\u00e8","year":"2000","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.tim.2025.11.003_bb0465","first-page":"214","article-title":"Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up","volume":"3","author":"Palmero","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012137","article-title":"A protective role for type I interferon signaling following infection with Mycobacterium tuberculosis carrying the rifampicin drug resistance-conferring RpoB mutation H445Y","volume":"20","author":"Bobba","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2025.11.003_bb0475","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/414027","article-title":"Successive intramuscular boosting with IFN-alpha protects Mycobacterium bovis BCG-vaccinated mice against M. lepraemurium infection","volume":"2015","author":"Guerrero","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tim.2025.11.003_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8796760","article-title":"IFN-\u03b1 boosting of Mycobacterium bovis Bacillus Calmette G\u00fcerin-vaccine promoted Th1 type cellular response and protection against M. tuberculosis infection","volume":"2017","author":"Rivas-Santiago","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tim.2025.11.003_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.592333","article-title":"NOD2\/RIG-I activating inarigivir adjuvant enhances the efficacy of BCG vaccine against tuberculosis in mice","volume":"11","author":"Khan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0490","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/infdis\/jiz116","article-title":"Bacillus Calmette-Gu\u00e9rin overexpressing an endogenous stimulator of interferon genes agonist provides enhanced protection against pulmonary tuberculosis","volume":"221","author":"Dey","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0495","article-title":"Increased vaccine efficacy against tuberculosis with a recombinant BCG overexpressing the STING agonist cyclic di-AMP","author":"Singh","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.tim.2025.11.003_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2020.101949","article-title":"Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon","volume":"123","author":"Troy","year":"2020","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tim.2025.11.003_bb0505","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.20060401","article-title":"Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation","volume":"203","author":"Guiducci","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0510","article-title":"Blood transcriptional correlates of BCG-induced protection against tuberculosis in rhesus macaques","volume":"4","author":"Liu","year":"2023","journal-title":"CR Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tim.2025.11.003_bb0520","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/vaccines12050477","article-title":"Promising cytokine adjuvants for enhancing tuberculosis vaccine immunity","volume":"12","author":"Cao","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.tim.2025.11.003_bb0525","author":"Borges","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2025.11.003_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-57090-4","article-title":"Prevention of tuberculosis in cynomolgus macaques by an attenuated Mycobacterium tuberculosis vaccine candidate","volume":"16","author":"Singh","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0535","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.4049\/jimmunol.1101313","article-title":"Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing","volume":"188","author":"Simmons","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0540","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Cutting edge: Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation1","volume":"174","author":"Curtsinger","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0545","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.tim.2021.01.007","article-title":"Impact of Type I interferons on susceptibility to bacterial pathogens","volume":"29","author":"Peignier","year":"2021","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tim.2025.11.003_bb0550","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1038\/s41467-022-30914-3","article-title":"Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx","volume":"13","author":"Kang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0555","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature13801","article-title":"Human intracellular ISG15 prevents interferon-\u03b1\/\u03b2 over-amplification and auto-inflammation","volume":"517","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.tim.2025.11.003_bb0560","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.2353\/ajpath.2010.091158","article-title":"Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice","volume":"176","author":"Meissner","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tim.2025.11.003_bb0565","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.1224026","article-title":"Mycobacterial disease and impaired IFN-\u03b3 immunity in humans with inherited ISG15 deficiency","volume":"337","author":"Bogunovic","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.tim.2025.11.003_bb0570","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/cells11030538","article-title":"ISG15 and ISGylation in human diseases","volume":"11","author":"Mirzalieva","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.tim.2025.11.003_bb0575","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1164\/rccm.201408-1502OC","article-title":"The DosR regulon modulates adaptive immunity and is essential for Mycobacterium tuberculosis persistence","volume":"191","author":"Mehra","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0580","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1073\/pnas.1711373114","article-title":"In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis","volume":"115","author":"Gautam","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tim.2025.11.003_bb0585","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41590-021-01121-x","article-title":"The immunoregulatory landscape of human tuberculosis granulomas","volume":"23","author":"McCaffrey","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0590","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.779739","article-title":"Hypoxia regulates endogenous double-stranded RNA production via reduced mitochondrial DNA transcription","volume":"11","author":"Arnaiz","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tim.2025.11.003_bb0595","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm.3412","article-title":"Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing","volume":"20","author":"Lin","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.tim.2025.11.003_bb0600","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.chom.2024.11.008","article-title":"Type I IFN-mediated NET release promotes Mycobacterium tuberculosis replication and is associated with granuloma caseation","volume":"32","author":"Chowdhury","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2025.11.003_bb0605","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1038\/ncomms9533","article-title":"Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis","volume":"6","author":"Kaushal","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.11.003_bb0610","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/eji.200737184","article-title":"On watching the watchers: IDO and type I\/II IFN","volume":"37","author":"Puccetti","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tim.2025.11.003_bb0615","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03189-21","article-title":"Myeloid-derived suppressor cells mediate T cell dysfunction in nonhuman primate TB granulomas","volume":"12","author":"Singh","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.tim.2025.11.003_bb0620","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00021-18","article-title":"Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection","volume":"31","author":"Drain","year":"2018","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X25003294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X25003294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:42:13Z","timestamp":1773715333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X25003294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0966842X25003294"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2025.11.003","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I interferons in tuberculosis pathogenesis and prevention","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}